72571-06-3

Usage

Uses

Used in Pharmaceutical Industry:
5-(4-BROMOPHENYL)-1,3-OXAZOLE is used as a key intermediate in the synthesis of various medicinal drugs. Its unique structure and properties enable the development of new chemical entities with potential therapeutic applications, contributing to the advancement of pharmaceutical research and drug discovery.
Used in Agrochemical Industry:
In the agrochemical sector, 5-(4-BROMOPHENYL)-1,3-OXAZOLE serves as a building block for the creation of effective pesticides. Its incorporation into the molecular structure of these compounds enhances their biological activity, leading to improved pest control and crop protection.
Used in Chemical Research and Development:
5-(4-BROMOPHENYL)-1,3-OXAZOLE is utilized in chemical research and development processes for the exploration and creation of new chemical entities and materials. Its unique properties make it a valuable intermediate in organic synthesis, facilitating the discovery of novel compounds with diverse applications across various industries.

InChI:InChI=1/C9H6BrNO/c10-8-3-1-7(2-4-8)9-5-11-6-12-9/h1-6H

Upstream product

• 5467-72-1 α-amino-4-bromoacetophenone hydrochloride 
• 122-51-0 orthoformic acid triethyl ester 
• 38622-91-2 [(p-methylphenyl)sulfonylmethyl]isonitrile 
• 1122-91-4 4-bromo-benzaldehyde 
• 7099-87-8 4-bromophenylglyoxylic acid 
• 99-73-0 para-bromophenacyl bromide 
• 72571-04-1 ethyl [[2-(4-bromophenyl)-2-oxoethyl]amino]oxoacetate 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 873-75-6 4-bromobenzenemethanol 
• 68-12-2 N,N-dimethyl-formamide 
• 55605-27-1 (4-bromophenyl)methylenediacetate 
• 77287-34-4 formamide 
• 72571-05-2 ethyl 5-(4-bromophenyl)oxazole-2-carboxylate 

Downstream Products

• 282117-22-0 5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)oxazole 
• 1021919-20-9 5-(4-(trimethylstannyl)phenyl)oxazole 
• 501121-15-9 (5-(4-bromophenyl)oxazol-2-yl)(phenyl)methanone 
• 1145-12-6 5-([1,1'-biphenyl]-4-yl)oxazole 

Relevant academic research and scientific papers

INHIBITOR COMPOUNDS

The disclosure relates to heterocyclic compounds and methods for their preparation. The disclosure provides compounds that may have beneficial therapeutic activity in the treatment of a disease or condition mediated by excessive or otherwise undesirable Des1 and/or fibrotic activity.

PISTON FOR AN INTERNAL COMBUSTION ENGINE AND METHOD FOR PRODUCING THE PISTON FOR AN INTERNAL COMBUSTION ENGINE

The present invention relates to compounds of general formula (I), wherein A represents an optionally substituted heterocycle group, B represents an aryl or heteroaryl group and wherein X, R1, R2, R3, R4 and R5 are as defined in the description. Compounds of formula (I) are useful to destroy, inhibit, or prevent the growth or spread of cells, especially malignant cells, into surrounding tissues implicated in a variety of human and animal diseases.

Libraries of C-5 Substituted Imidazoles and Oxazoles by Sequential Van Leusen (VL)–Suzuki, VL–Heck and VL–Sonogashira in Imidazolium-ILs with Piperidine-Appended-IL as Base

Facile access to diverse C5-substituted imidazoles and oxazoles via sequential Van Leusen–Suzuki, Van Leusen–Heck, and Van Leusen–Sonogashira protocols, employing imidazolium-ILs as solvents along with piperidine-appended imidazolium [PAIM][NTf2/sub

COMPOUNDS WITH ANTI-TUMORAL ACTIVITY

The present invention relates to compounds of general formula (I), wherein A represents an optionally substituted heterocycle group, B represents an aryl or heteroaryl group and wherein X, R1, R2, R3, R4 and R5 are as defined in the description. Compounds of formula (I) are useful to destroy, inhibit, or prevent the growth or spread of cells, especially malignant cells, into surrounding tissues implicated in a variety of human and animal diseases.

Tandem cycloaddition-decarboxylation of α-keto acid and isocyanide under oxidant-free conditions towards monosubstituted oxazoles

An efficient method, tandem [3 + 2] cycloaddition-decarboxylation of α-keto acid and isocyanide promoted by copper salt, has been developed. Under oxidant-free conditions, a series monosubstituted oxazoles have been constructed. Different from the traditional application of α-oxo acids as acyl surrogates, the elegant approach herein ingeniously avoids consuming excess oxidants.

A One-Pot Tandem Approach for the Synthesis of 5-(Het)aryloxazoles from Substituted (Het)aryl Methyl Alcohols and Benzyl Bromides

A new modified van Leusen strategy has been developed for the synthesis of biologically significant 5-substituted oxazoles by the reaction of (het)aryl methyl alcohols or benzyl bromides as precursors with tosylmethylisocyanide (TosMIC) under basic conditions. This method is efficient, takes place under mild reaction conditions, and is tolerant of various functional groups with high yield.

Cobalt-Catalyzed Decarboxylative 2-Benzoylation of Oxazoles and Thiazoles with α-Oxocarboxylic Acids

Cobalt-catalyzed decarboxylative cross-coupling of oxazoles and thiazoles with α-oxocarboxylic acids was developed through an sp2 C-H bond functionalization process. This work represents the first example of cobalt-catalyzed decarboxylative C-H

Nickel-catalyzed decarboxylative acylation of heteroarenes by sp 2 C-H functionalization

Nickel-catalyzed ligand-free decarboxylative cross-coupling of azole derivatives with α-oxoglyoxylic acids has been developed. This work represents the first example of decarboxylative cross-coupling reactions, in a C-H bond functionalization manner, thro

Nickel-catalyzed decarboxylative arylation of heteroarenes through sp2 C-H functionalization

The direct decarboxylative arylation of hetereoarenes with benzoic acids through a nickel-catalyzed sp2 C-H functionalization process was developed. This process provides the first examples of decarboxylative cross-coupling reactions with aroma

Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2- ones as potent and selective mTOR kinase inhibitors

We report here the discovery of a novel series of selective mTOR kinase inhibitors. A series of imidazo[4,5-b]pyrazin-2-ones, represented by screening hit 1, was developed into lead compounds with excellent mTOR potency and exquisite kinase selectivity. Potent compounds from this series show >1000-fold selectivity over the related PI3Kα lipid kinase. Further, compounds such as 2 achieve mTOR pathway inhibition, blocking both mTORC1 and mTORC2 signaling, in PC3 cancer cells as measured by inhibition of pS6 and pAkt (S473).